Investigational Parkinson’s disease dementia therapy fails in clinical trial


Author: Sophie ParrottPublished: 16 March 2023

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

Cognitive function.

Research into new potential therapies for people with Parkinson’s is complex, which means that not all clinical trials will successfully move on to the next phase.

This proved to be the case for US biotech company Aptinyx, which announced that it will halt further development work on an investigational therapy following “disappointing” results in the second phase of its study.

The research had set out to examine the effect of NYX-458 – an oral therapy created to modulate the activity of receptors in the brain that are responsible for communication between neurons. The aim of the therapy was to improve cognition in people with cognitive impairment linked to Parkinson’s or Lewy body dementia. Yet, when compared to a placebo, the therapy didn’t demonstrate “meaningful improvements” in cognitive function.

Dr Andy Kidd, president and CEO at Aptinyx, said: “We are very disappointed that the results of this Phase 2 study did not validate the therapeutic potential observed previously in preclinical studies of NYX-458 in models of cognitive impairment.”

Read more:

Researchers present in-depth review of 145 clinical trials for Parkinson’s

A new “promising approach” to Parkinson’s disease treatment?

Go Back

Share this story


Related articles

Close-up of African senior man in grey wool jumper leaning on his stick

Global update

How does the impact of DBS vary across Parkinson’s disease subtypes?

Exploring the treatment’s effect on non-motor symptoms

Stem cells


A new “promising approach” to Parkinson’s disease treatment?

Read about an upcoming research trial from Sweden and the UK

A group of scientists in white lab coats.

Global update

Call for increased research into drug targets for neurodegenerative conditions

What could this achieve for people with Parkinson’s disease?